Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Labcorp launches at-home collection device for diabetes risk testing
Labcorp (NYSE:LH) announced today that it launched an at-home collection kit that measures HbA1c from a small blood sample. Burlington, North Carolina-based Labcorp’s first-of-its-kind diagnostic offering uses a collection device from Weavr Health and is offered through its Labcorp OnDemand platform. Get the full story at our sister site, Drug Delivery Business News.
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented […]
Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
The future for Insulet (Nasdaq:PODD) has a different look than it did about a week ago. A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced she would step down as president and CEO for personal reasons. Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin […]
Senseonics beats The Street in Q1 following Eversense E3 launch
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a […]
Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role
Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons. Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to […]
Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’
Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast. The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago […]
Tandem stock down after Q1 EPS miss
Tandem Diabetes Care (Nasdaq:TNDM) shares are down today, a day after first-quarter results that were mixed compared to the consensus forecast. The San Diego-based automated insulin delivery technology developer posted losses of $14.7 million, or 23¢ per share, on sales of $175.9 million for the three months ended March 31, 2022, for a bottom-line slide […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Beta Bionics says iLet bionic pancreas reduces HbA1c and improves time in range for T1D
Beta Bionics announced positive results from a pivotal trial of its iLet bionic pancreas for the delivery of insulin in diabetes patients. Concord, Massachusetts-based Beta Bionics designed the pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter bodyweight to initialize therapy without the need for insulin regimen […]
Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system
Ascensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system. The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels. Get the […]